Aptus Biotech participates since June 2019 of the project METASTARG (TARGETED MULTIFUNCTIONAL NANOEMULSIONS TO INTERRUPT METASTATIC PROGRESSION) which has been founded by CDTI (Centre for the Development of Industrial Technology) and FEDER (European Regional Development Fund) through the Euronanomed 2018 call. It is a translational approach that combines innovative research in the field of nanomedicine to provide solutions to an urgent clinical need, improving survival of patients with NSCLC by developing innovative nanotechnologies for detection of OM by non-invasive imaging techniques, and simultaneous delivery of chemotherapeutics to interrupt metastasis progression. The consortium is integrated by the Group of Oncología Médica del Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS) y Centro de Investigación Biomédica en Red, M.P. (CIBER) bajo la dirección de María de la Fuente. As partners, International Iberian Nanotechnology Laboratory (INL) (Portugal), Fondazione IRCCS Istituto Nazionale dei Tumori (INDT) Italy, Holochem (France), Institute of Physical Chemistry “Ilie Murgulescu” of the Romanian Academy y Aptus Biotech.